NF2
MCID: NRF023
MIFTS: 80

Neurofibromatosis, Type Ii (NF2)

Categories: Bone diseases, Cardiovascular diseases, Ear diseases, Eye diseases, Fetal diseases, Genetic diseases, Nephrological diseases, Neuronal diseases, Rare diseases, Skin diseases

Aliases & Classifications for Neurofibromatosis, Type Ii

MalaCards integrated aliases for Neurofibromatosis, Type Ii:

Name: Neurofibromatosis, Type Ii 56 37
Acne 12 74 29 42 15 62 17 71 32
Neurofibromatosis 2 12 24 25 73 43 15 71
Acne Vulgaris 12 74 54 43 15 71 32
Nf2 56 12 24 52 25 58 73
Neurofibromatosis Type 2 74 52 25 58 36 54
Neurofibromatosis, Type 2 56 29 13 6 39
Neurofibromatosis Type Ii 12 74 24 52 25
Bilateral Acoustic Neurofibromatosis 56 12 52 25
Central Neurofibromatosis 12 25 73
Acne Varioliformis 12 71 32
Banf 56 12 25
Familial Acoustic Neuromas 12 25
Acn 56 12
Bilateral Acoustic Neurofibromatosis; Banf 56
Acoustic Neurinoma, Bilateral; Acn 56
Neurofibromatosis, Central Type 56
Acoustic Schwannomas, Bilateral 56
Schwannoma, Acoustic, Bilateral 25
Bilateral Acoustic Schwannomas 12
Acoustic Schwannomas Bilateral 52
Neurofibromatosis Central Type 52
Acoustic Neurinoma, Bilateral 56
Bilateral Acoustic Neurinoma 12
Acoustic Neurinoma Bilateral 52
Frontalis Acne 12

Characteristics:

Orphanet epidemiological data:

58
neurofibromatosis type 2
Inheritance: Autosomal dominant; Prevalence: 1-9/100000 (Europe),1-9/100000 (United Kingdom),1-9/100000 (Finland); Age of onset: All ages;

OMIM:

56
Inheritance:
autosomal dominant

Miscellaneous:
incidence of 1 in 25,000 livebirths
nearly 100% penetrance by 60 years of age
approximately half of the mutations are de novo


HPO:

31
neurofibromatosis, type ii:
Inheritance autosomal dominant inheritance


GeneReviews:

24
Penetrance Penetrance is close to 100%. virtually all individuals who have a germline pathogenic variant develop the disease in an average lifetime....

Classifications:

Orphanet: 58  
Rare neurological diseases
Rare eye diseases
Rare otorhinolaryngological diseases
Developmental anomalies during embryogenesis


Summaries for Neurofibromatosis, Type Ii

Genetics Home Reference : 25 Neurofibromatosis type 2 is a disorder characterized by the growth of noncancerous tumors in the nervous system. The most common tumors associated with neurofibromatosis type 2 are called vestibular schwannomas or acoustic neuromas. These growths develop along the nerve that carries information from the inner ear to the brain (the auditory nerve). Tumors that occur on other nerves are also commonly found with this condition. The signs and symptoms of neurofibromatosis type 2 usually appear during adolescence or in a person's early twenties, although they can begin at any age. The most frequent early symptoms of vestibular schwannomas are hearing loss, ringing in the ears (tinnitus), and problems with balance. In most cases, these tumors occur in both ears by age 30. If tumors develop elsewhere in the nervous system, signs and symptoms vary according to their location. Complications of tumor growth can include changes in vision, numbness or weakness in the arms or legs, and fluid buildup in the brain. Some people with neurofibromatosis type 2 also develop clouding of the lens (cataracts) in one or both eyes, often beginning in childhood.

MalaCards based summary : Neurofibromatosis, Type Ii, also known as acne, is related to malignant pleural mesothelioma and malignant peripheral nerve sheath tumor, and has symptoms including ataxia, pruritus and headache. An important gene associated with Neurofibromatosis, Type Ii is NF2 (Neurofibromin 2), and among its related pathways/superpathways are Hippo signaling pathway and Developmental Biology. The drugs Lymecycline and Hydroquinone have been mentioned in the context of this disorder. Affiliated tissues include skin, ovary and brain, and related phenotypes are sensorineural hearing impairment and tinnitus

Disease Ontology : 12 A sebaceous gland disease characterized by areas of blackheads, whiteheads, pimples, greasy skin, and possibly scarring.

NIH Rare Diseases : 52 Neurofibromatosis type 2 (NF2) is a disorder characterized by the growth of noncancerous tumors of the nervous system. Childhood symptoms include skin growths and eye findings. Almost all people with NF2 develop vestibular schwannomas affecting both ears by age 30. Other tumors of the central nervous system (the brain and spinal cord), skin and eye are also common. The signs and symptoms vary from person to person. The severity depends on the size, location, and number of tumors. NF2 is caused by changes (mutations ) in the NF2 gene and is inherited in an autosomal dominant manner. It is diagnosed based on a clinical examination and the symptoms. Genetic testing may be helpful. The treatment is based on managing the signs and symptoms and may include surgery and medications.

OMIM : 56 The central or type II form of neurofibromatosis (NF2) is an autosomal dominant multiple neoplasia syndrome characterized by tumors of the eighth cranial nerve (usually bilateral), meningiomas of the brain, and schwannomas of the dorsal roots of the spinal cord. The incidence of neurofibromatosis type II is 1 in 25,000 live births (Asthagiri et al., 2009). NF2 has few of the hallmarks of the peripheral or type I form of neurofibromatosis (NF1; 162200), also known as von Recklinghausen disease. Asthagiri et al. (2009) provided a detailed review of neurofibromatosis type II. (101000)

MedlinePlus : 42 Acne is a common skin disease that causes pimples. Pimples form when hair follicles under your skin clog up. Most pimples form on the face, neck, back, chest, and shoulders. Anyone can get acne, but it is common in teenagers and young adults. It is not serious, but it can cause scars. No one knows exactly what causes acne. Hormone changes, such as those during the teenage years and pregnancy, probably play a role. There are many myths about what causes acne. Chocolate and greasy foods are often blamed, but there is little evidence that foods have much effect on acne in most people. Another common myth is that dirty skin causes acne; however, blackheads and pimples are not caused by dirt. Stress doesn't cause acne, but stress can make it worse. If you have acne Clean your skin gently Try not to touch your skin Avoid the sun Treatments for acne include medicines and creams. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

KEGG : 36 Neurofibromatosis 2 (NF2) is a rare autosomal dominant multiple neoplasia syndrome that is caused by inactivating mutations of the NF2 tumour suppressor gene. The course of the disease is usually progressive, though variable, causing significant morbidity associated with deafness, blindness, brain stem compression, gait instability, and paralysis. Onset typically occurs while a patient is in their 20s. Vestibular schwannomas, usually bilateral, occur in more than 90% of adult patients and intracranial meningiomas occur in about 50% of patients.

UniProtKB/Swiss-Prot : 73 Neurofibromatosis 2: Genetic disorder characterized by bilateral vestibular schwannomas (formerly called acoustic neuromas), schwannomas of other cranial and peripheral nerves, meningiomas, and ependymomas. It is inherited in an autosomal dominant fashion with full penetrance. Affected individuals generally develop symptoms of eighth-nerve dysfunction in early adulthood, including deafness and balance disorder. Although the tumors of NF2 are histologically benign, their anatomic location makes management difficult, and patients suffer great morbidity and mortality.

PubMed Health : 62 About acne: Most teenagers will have pimples at some point. Some only have a few small pimples that soon go away again. Others develop more severe, persistent and clearly visible acne. This can be very distressing, particularly in puberty. But there are a number of things that can be done about acne, although patience is needed. This information is about acne in teenagers and young adults, known as “common acne or acne vulgaris.

Wikipedia : 74 Neurofibromatosis type II (also known as MISME syndrome - multiple inherited schwannomas, meningiomas,... more...

GeneReviews: NBK1201

Related Diseases for Neurofibromatosis, Type Ii

Diseases in the Neurofibromatosis family:

Neurofibromatosis, Type Ii Neurofibromatosis, Type I

Diseases related to Neurofibromatosis, Type Ii via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 996)
# Related Disease Score Top Affiliating Genes
1 malignant pleural mesothelioma 33.5 NF2 EGFR AKT1
2 malignant peripheral nerve sheath tumor 33.0 NF2 NF1 EGFR CD44
3 benign ependymoma 33.0 NF2 NF1 EGFR
4 malignant peritoneal mesothelioma 32.8 NF2 EGFR
5 tanycytic ependymoma 32.7 SLC9A3R1 NF2
6 gastrointestinal stromal tumor 32.7 NF2 NF1 EGFR CD44 AKT1
7 brain cancer 32.4 NF2 NF1 EZR EPB41L3 EGFR CD44
8 cellular schwannoma 32.3 NF2 NF1
9 epithelioid neurofibroma 32.3 NF2 NF1
10 plexiform schwannoma 32.3 NF2 NF1
11 optic nerve sheath meningioma 32.2 NF2 NF1
12 spinal cancer 32.2 NF2 NF1 EPB41L3
13 peripheral nerve schwannoma 32.2 SPTBN1 NF2 NF1
14 psammomatous meningioma 32.2 SLC9A3R1 NF2
15 meninges hemangiopericytoma 32.2 NF2 EPB41L3
16 small intestine leiomyoma 32.2 NF2 NF1
17 central nervous system benign neoplasm 32.2 NF2 NF1 AKT1
18 polyp of corpus uteri 32.1 NF2 NF1
19 pleural cancer 32.1 NF2 EGFR AKT1
20 orbital cancer 32.1 NF2 NF1
21 optic nerve neoplasm 32.1 NF2 NF1
22 peripheral nervous system neoplasm 32.0 NF2 NF1 EGFR AKT1
23 cowden syndrome 32.0 NF2 NF1 EGFR AKT1
24 central nervous system cancer 32.0 NF2 NF1 EGFR AKT1
25 spinal canal and spinal cord meningioma 32.0 NF2 NF1
26 sebaceous gland disease 31.3 TLR2 SHBG EGFR DEFB4A
27 acoustic neuroma 30.8 RDX NF2 NF1 MSN EZR
28 neurilemmoma 30.7 RDX NF2 NF1 MSN EZR AKT1
29 spinal meningioma 30.7 NF2 NF1
30 meningioma, radiation-induced 30.6 RDX NF2 MSN EZR EPB41L3 CADM1
31 neurofibroma 30.5 NF2 NF1 EGFR
32 vulvovaginal candidiasis 30.5 TLR2 DEFB4A DEFB1
33 periodontitis 30.3 TLR2 DEFB4A DEFB1
34 meningioma, familial 30.3 SLC9A3R1 RDX NF2 NF1 MSN EZR
35 ductal carcinoma in situ 30.0 EGFR CD44 AKT1
36 pathologic nystagmus 30.0 RDX MSN EZR
37 cystic fibrosis 30.0 TLR2 SLC9A3R1 EZR DEFB4A DEFB1
38 eye disease 29.8 TLR2 DEFB4A DEFB1 CD44 AKT1
39 retinal dystrophy, iris coloboma, and comedogenic acne syndrome 12.8
40 pyogenic sterile arthritis, pyoderma gangrenosum, and acne 12.8
41 acne inversa, familial, 3 12.7
42 acne inversa, familial, 1 12.7
43 acne inversa, familial, 2, with or without dowling-degos disease 12.7
44 pyoderma gangrenosum-acne-suppurative hidradenitis syndrome 12.4
45 acne, adult 12.3
46 hidradenitis suppurativa 12.3
47 rosacea 12.1
48 schwannomatosis 1 12.0
49 anterior cutaneous nerve entrapment syndrome 11.9
50 sapho syndrome 11.9

Graphical network of the top 20 diseases related to Neurofibromatosis, Type Ii:



Diseases related to Neurofibromatosis, Type Ii

Symptoms & Phenotypes for Neurofibromatosis, Type Ii

Human phenotypes related to Neurofibromatosis, Type Ii:

58 31 (show top 50) (show all 69)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 sensorineural hearing impairment 58 31 hallmark (90%) Frequent (79-30%) HP:0000407
2 tinnitus 58 31 very rare (1%) Occasional (29-5%) HP:0000360
3 ataxia 31 very rare (1%) HP:0001251
4 vertigo 31 very rare (1%) HP:0002321
5 cataract 31 frequent (33%) HP:0000518
6 migraine 31 frequent (33%) HP:0002076
7 sensory neuropathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0000763
8 facial palsy 58 31 occasional (7.5%) Occasional (29-5%) HP:0010628
9 meningioma 58 31 very rare (1%) Frequent (79-30%) HP:0002858
10 astrocytoma 58 31 occasional (7.5%) Very rare (<4-1%) HP:0009592
11 corneal opacity 31 occasional (7.5%) HP:0007957
12 increased intracranial pressure 31 occasional (7.5%) HP:0002516
13 visual impairment 31 occasional (7.5%) HP:0000505
14 gait disturbance 31 occasional (7.5%) HP:0001288
15 subcutaneous nodule 31 occasional (7.5%) HP:0001482
16 papule 31 occasional (7.5%) HP:0200034
17 multiple cafe-au-lait spots 31 occasional (7.5%) HP:0007565
18 dysgraphia 31 occasional (7.5%) HP:0010526
19 pseudoepiphyses of the metacarpals 31 occasional (7.5%) HP:0009193
20 occasional neurofibromas 31 occasional (7.5%) HP:0009595
21 abnormal retinal vascular morphology 31 occasional (7.5%) HP:0008046
22 retinal hamartoma 58 31 very rare (1%) Occasional (29-5%) HP:0009594
23 ependymoma 58 31 very rare (1%) Occasional (29-5%) HP:0002888
24 bilateral vestibular schwannoma 58 31 very rare (1%) Frequent (79-30%) HP:0009589
25 cortical cataract 58 31 very rare (1%) Occasional (29-5%) HP:0100019
26 hearing impairment 31 very rare (1%) HP:0000365
27 cafe-au-lait spot 31 very rare (1%) HP:0000957
28 seizure 31 very rare (1%) HP:0001250
29 juvenile posterior subcapsular lenticular opacities 31 very rare (1%) HP:0007935
30 unilateral vestibular schwannoma 31 very rare (1%) HP:0009590
31 peripheral schwannoma 58 31 Frequent (79-30%) HP:0009593
32 epiretinal membrane 58 31 Occasional (29-5%) HP:0100014
33 seizures 58 Occasional (29-5%)
34 hydrocephalus 58 Occasional (29-5%)
35 blindness 58 Occasional (29-5%)
36 cranial nerve paralysis 58 Occasional (29-5%)
37 dysphagia 58 Occasional (29-5%)
38 peripheral neuropathy 31 HP:0009830
39 memory impairment 58 Occasional (29-5%)
40 dysarthria 58 Occasional (29-5%)
41 abnormality of the eye 58 Frequent (79-30%)
42 amblyopia 58 Occasional (29-5%)
43 neoplasm of the skin 58 Occasional (29-5%)
44 reduced visual acuity 58 Frequent (79-30%)
45 glioma 58 Very rare (<4-1%)
46 headache 31 HP:0002315
47 remnants of the hyaloid vascular system 58 Very rare (<4-1%)
48 abnormal cerebellum morphology 58 Occasional (29-5%)
49 spinal cord tumor 58 Frequent (79-30%)
50 hyperesthesia 58 Frequent (79-30%)

Symptoms via clinical synopsis from OMIM:

56
Neurologic Central Nervous System:
ataxia
headache

Neoplasia:
glioma
meningioma
astrocytoma
ependymoma
vestibular schwannoma (over 90% of patients)
more
Head And Neck Ears:
tinnitus
hearing loss

Neurologic Peripheral Nervous System:
peripheral neuropathy

Head And Neck Eyes:
retinal hamartoma
juvenile posterior subcapsular lenticular opacities
juvenile cortical cataract
epiretinal membranes
no lisch nodules

Skin Nails Hair Skin:
schwannoma
occasional cafe-au-lait spots
occasional neurofibroma

Clinical features from OMIM:

101000

UMLS symptoms related to Neurofibromatosis, Type Ii:


ataxia, pruritus, headache, tinnitus, exanthema

GenomeRNAi Phenotypes related to Neurofibromatosis, Type Ii according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.9 NF2 AKT1
2 Decreased cell migration GR00055-A-3 9.9 EGFR PXN RDX SDCBP
3 Decreased viability GR00055-A-1 9.4 EGFR PXN RDX SDCBP
4 Decreased viability GR00055-A-2 9.4 EGFR PXN RDX SDCBP
5 Decreased viability GR00221-A-1 9.4 EGFR
6 Decreased viability GR00221-A-4 9.4 EGFR
7 Decreased viability GR00249-S 9.4 PXN
8 Decreased viability GR00386-A-1 9.4 RDX
9 Decreased p24 protein expression GR00163-A-1 9.26 AKT1 EGFR NF2 SPTBN1

MGI Mouse Phenotypes related to Neurofibromatosis, Type Ii:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.3 AKT1 CADM1 CD44 EGFR EPB41L3 ETV5
2 growth/size/body region MP:0005378 10.26 AKT1 CADM1 CD44 EGFR ETV5 EZR
3 mortality/aging MP:0010768 10.25 AKT1 CD44 EGFR EPB41L3 ETV5 EZR
4 endocrine/exocrine gland MP:0005379 10.19 AKT1 CADM1 CD44 EGFR EPB41L3 ETV5
5 nervous system MP:0003631 10.17 AKT1 CADM1 CD44 EGFR EPB41L3 ETV5
6 digestive/alimentary MP:0005381 10.16 CD44 EGFR EZR HGS NF1 PXN
7 liver/biliary system MP:0005370 10.03 AKT1 CD44 EGFR NF1 NF2 RDX
8 neoplasm MP:0002006 9.97 AKT1 CD44 EGFR EPB41L3 NF1 NF2
9 hearing/vestibular/ear MP:0005377 9.93 EGFR HGS NF1 NF2 RDX SPTBN1
10 reproductive system MP:0005389 9.93 AKT1 CADM1 CD44 EGFR EPB41L3 ETV5
11 renal/urinary system MP:0005367 9.86 CD44 EGFR ETV5 NF1 NF2 SLC9A3R1
12 respiratory system MP:0005388 9.56 AKT1 CD44 EGFR ETV5 MSN NF1
13 skeleton MP:0005390 9.28 AKT1 CD44 EGFR ETV5 HGS NF1

Drugs & Therapeutics for Neurofibromatosis, Type Ii

PubMed Health treatment related to Neurofibromatosis, Type Ii: 62

People with acne often try out different things to improve the appearance of their skin . There are a lot of different recommendations when it comes to acne, involving things like facial toners, sunlight and specific diets. There are also a number of medications for acne . Some are applied to the skin , some are swallowed. Because you can buy them without a prescription, many of the products are heavily marketed. But advert ising campaigns often create unrealistic expectations. Some treatment approaches and medications have been proven to effectively reduce acne, while others have not. Unfortunately there are only a few good-quality studies comparing the various treatments with each other. So it is not possible to tell whether certain products are more effective than others. Most products have to be used for a long time before there is a noticeable improvement. And some have strong side effects.

Drugs for Neurofibromatosis, Type Ii (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 451)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lymecycline Approved, Investigational Phase 4 992-21-2 5280963
2
Hydroquinone Approved, Investigational Phase 4 123-31-9 785
3
carbamide peroxide Approved Phase 4 124-43-6
4
Ciclopirox Approved, Investigational Phase 4 29342-05-0 2749
5
Adapalene Approved Phase 4 106685-40-9 60164
6
Coal tar Approved Phase 4 8007-45-2
7
Azelaic acid Approved Phase 4 123-99-9 2266
8
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
9
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
10
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
11
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
12
Desogestrel Approved Phase 4 54024-22-5 40973
13
Ketoconazole Approved, Investigational Phase 4 65277-42-1 47576
14
Tetracaine Approved, Vet_approved Phase 4 94-24-6 5411
15
Clobetasol Approved, Experimental, Investigational Phase 4 25122-41-2, 25122-46-7 32798 5311051
16
Petrolatum Approved, Investigational Phase 4 8009-03-8
17
Desonide Approved, Investigational Phase 4 638-94-8 5311066
18
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
19
Loteprednol Approved, Experimental Phase 4 129260-79-3, 82034-46-6 9865442 444025
20
leucovorin Approved Phase 4 58-05-9 6006 143
21
Dapsone Approved, Investigational Phase 4 80-08-0 2955
22
Aminolevulinic acid Approved Phase 4 106-60-5 137
23
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
24
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
25
Drospirenone Approved Phase 4 67392-87-4 68873
26
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
27
Polyestradiol phosphate Approved Phase 4 28014-46-2
28
Chamomile Approved, Experimental, Investigational Phase 4
29
Caffeine Approved Phase 4 58-08-2 2519
30
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560 441411
31
Adalimumab Approved Phase 4 331731-18-1 16219006
32
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
33
Acetaminophen Approved Phase 4 103-90-2 1983
34
Spironolactone Approved Phase 4 52-01-7, 1952-01-7 5833
35
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 10204 6013
36
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
37
Sage Approved Phase 4
38
Methyltestosterone Approved Phase 4 58-18-4 6010
39
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
40
Testosterone enanthate Approved Phase 4 315-37-7 9416
41
Metformin Approved Phase 4 657-24-9 14219 4091
42
Tazarotene Approved, Investigational Phase 4 118292-40-3 5381
43
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
44
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
45
Racepinephrine Approved Phase 4 329-65-7 838
46
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
47
Prilocaine Approved Phase 4 721-50-6 4906
48
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
49
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
50
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741

Interventional clinical trials:

(show top 50) (show all 840)
# Name Status NCT ID Phase Drugs
1 A Pilot Study to Evaluate the Safety and Tolerability of CeraVe® Lotion Followed by Fixed Dose Clindamycin Phosphate 1.2% / Benzoyl Peroxide 2.5% Gel in the Morning in Combination With CeraVe® Lotion Followed by Tretinoin 0.05% Gel in the Evening for the Treatment of Facial Acne Vulgaris. Unknown status NCT01448733 Phase 4 Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning with with tretinoin 0.05% gel in the evening
2 Clinical Study to Evaluate the Efficacy of Topical Medications Containing Benzoyl Peroxide and Sulfur in the Regression in the Short Time (24 Hours) of Moderate Acne Vulgaris Grade II (Pimples) Unknown status NCT01260571 Phase 4 Benzoyl peroxide and sulfur
3 A Pilot Study to Evaluate the Efficacy of Fixed Dose Combination Clindamycin Phosphate 1.2%/Tretinoin 0.025% Gel Alone Versus Fixed Dose Combination Clindamycin Phosphate 1.2%/Tretinoin 0.025% Gel Plus Benzoyl Peroxide 6% Foaming Cloths in the Treatment of Facial Acne Vulgaris Unknown status NCT01422785 Phase 4 clindamycin phosphate 1.2%/tretinoin 0.025% gel alone;clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths
4 Control of Therapy of Acne Papulopustulosa by Visible Light With Waterfiltered Infrared and / or Adapalen (Differin Gel) Unknown status NCT00237978 Phase 4 Adapalen
5 Safety and Efficacy Comparison of Minocycline Microgranules vs Lymecycline in the Treatment of Mild to Moderate Acne. Randomized, Double Blind, Parallel and Prospective Clinical Trial for 8 Weeks Unknown status NCT00988026 Phase 4 Minocycline vs Lymecycline
6 Efficacy & Safety of Clindamycin Phosphase 1.2% and Tretinoin 0.025% Gel vs. Vehicle for the Treatment of Acne and Acne-Induced Post Inflammatory Hyperpigmentation in Patients With Skin of Color Unknown status NCT01111994 Phase 4 Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel
7 Efficacy & Safety of Azelaic Acid 15% Gel vs. Hydroquinone 4% Cream in the Treatment of Melasma Unknown status NCT00927771 Phase 4 azelaic acid gel;hydroquinone cream
8 A Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trials to Evaluate the Efficacy and Safety of Runzao Zhiyang Capsule in Treating Chronic Eczema Unknown status NCT02601222 Phase 4 Runzao zhiyang capsule;Runzaozhiyang capsule agent simulation;Urea cream
9 A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
10 Clinical, Laboratorial and Quality of Life Trial to Evaluate the Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea. Unknown status NCT01139749 Phase 4 oral isotretinoin;salicylic acid and ciclopirox olamine
11 Double-blind Placebo Controlled Trial of VSL#3 in Children With Crohn's Disease Unknown status NCT00367705 Phase 4
12 Prospective Evaluation of Perioperative Steroid Dosing on Postsurgical Edema in Orthognathic Surgery Unknown status NCT03190642 Phase 4 Methylprednisolone
13 A Study of Dapsone Gel in Females With Skin of Color and Acne Vulgaris Completed NCT02032407 Phase 4 Dapsone Gel
14 Evaluation of Efficacy and Safety of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris Completed NCT01149330 Phase 4 Adapalene-BPO Gel
15 Phase IV Clinical Study Of Clindamycin Phosphate Topical Gel In The Treatment Of Acne Vulgaris Completed NCT00219570 Phase 4 clindamycin;nadifloxacin
16 Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris Completed NCT01209949 Phase 4 Adapalene 0.1% and Benzoyl Peroxide 2.5% gel
17 An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris Completed NCT02959970 Phase 4 dapsone gel
18 Comparison of Efficacy and Safety of Tricilest (Norgestimate-ethinyl Estradiol) and Diane-35 (Cyproterone Acetate-ethinyl Estradiol) in the Treatment of Acne Vulgaris Completed NCT00752635 Phase 4 Norgestimate-ethinyl estradiol; Cyproterone acetate-ethinyl estradiol
19 Comparative Antimicrobial Efficacy of Two Topical Acne Therapies for the Treatment of Moderate to Moderately Severe Facial Acne Vulgaris Completed NCT00841776 Phase 4 Duac;Ziana gel
20 Dapsone Gel 5% and Tretinoin Gel 0.025% Versus Tretinoin Gel 0.025% Monotherapy for Facial Acne Vulgaris Completed NCT00835198 Phase 4 Dapsone; Tretinoin;Tretinoin
21 Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris Completed NCT00834210 Phase 4 Dapsone;Tazarotene
22 Anti P. Acnes Activity of Epiduo® Gel Compared to Benzoyl Peroxide (BPO) 2.5% Gel in the Treatment of Subjects With Acne Vulgaris Completed NCT01188538 Phase 4 Epiduo gel;BPO
23 A Clinical Assessment of Combination Therapy With Differin® Gel, 0.3% With Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris Completed NCT00671749 Phase 4 adapalene gel, 0.3%;clindamycin/benzoyl peroxide gel
24 Efficacy and Safety of Finacea in the Treatment of Post-Inflammatory Hyperpigmentation and Acne Vulgaris Completed NCT01038869 Phase 4 Azelaic acid
25 A Pilot, Multi-Center, Patient Preference Study Comparing Two Clindamycin/Benzoyl Peroxide Gels. Completed NCT00377000 Phase 4 clindamycin 1% / benzoyl peroxide 5% gel pump;clindamycin 1% / benzoyl peroxide 5% tube
26 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Doryx Tablets Compared to Doxycycline Hyclate in the Treatment of Acne Vulgaris. Completed NCT00635609 Phase 4 Doxycycline hyclate (Doryx);Doxycycline hyclate
27 A Multi-center, Randomized, Evaluator-blind, Parallel-group Evaluation of the Efficacy, Safety, and Tolerability of Duac Akne Gel and Epiduo Gel in the Topical Treatment of Facial Acne Vulgaris Completed NCT00757523 Phase 4 Epiduo Gel;Duac Gel
28 An Analysis of Adherence and Associated Factors in Subjects Undergoing Differin® Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris. Completed NCT00437151 Phase 4
29 A Multi-center, Randomized, Vehicle-controlled, Double-blind, Study to Evaluate the Safety and Efficacy of Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Administered Once Daily for the Treatment of Subjects 9 to 11 Years of Age With Acne Vulgaris Completed NCT01138735 Phase 4 adapalene/benzoyl peroxide;Topical Gel Vehicle
30 Adherence to ZIANA (Clindamycin Phosphate 1.2% With Tretinoin 0.025%)Gel Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris Completed NCT01047189 Phase 4 clindamycin phosphate 1.2% and tretinoin 0.025%;clindamycin 1% gel;tretinoin 0.025% cream
31 Multi-Centre, Single-Blind, Parallel Group, Clinical Evaluation of the Efficacy and Safety of Duac® Gel And Differin® Gel in the Topical Treatment of Mild to Moderate Acne Vulgaris Completed NCT00160394 Phase 4 Duac® Gel / Differin® Gel
32 Acne Free vs. Proactiv for the Treatment of Moderately Severe Acne Vulgaris Completed NCT00913185 Phase 4 Acne Free, Proactiv
33 Efficacy and Tolerability of Nicotinamide Plus Cream for Moderate Acne Vulgaris in Indonesia: A Multicenter Clinical Trial Completed NCT03626298 Phase 4 Adapalene;Nicotinamide, ABA and Zinc PCA;Placebos
34 A Multi-centre, Single-blind, Parallel Group, Clinical Evaluation of the Efficacy and Safety of Clindamycin 1% / Benzoyl Peroxide 3% and Azelaic Acid 20% in the Topical Treatment of Mild to Moderate Acne Vulgaris Completed NCT02058628 Phase 4 Clindamycin + BPO;Azelaic acid
35 Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris Completed NCT02944461 Phase 4 Dapsone 7.5 % gel
36 Single-blind, Multicenter, Parallel, Comparative, Randomized, Phase 4 Clinical Trial for the Evaluation of the Quality of Life, Efficacy and Tolerance of Duac® Gel Against Differin® Gel in the Topical Treatment of Mild to Moderate Acne Vulgaris. Completed NCT00807014 Phase 4 Duac Gel;Differin gel
37 An Open, Non-comparative Study of the Efficacy and Safety of Treatment of Acne Scars With Restylane Vital Lidocaine Completed NCT01807455 Phase 4
38 Efficacy and Safety of Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel Plus Doxycycline in Severe Inflammatory Acne (Non-Nodulocystic) Subjects Completed NCT02899000 Phase 4 Adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel;Oral doxycycline hyclate
39 Effect of Patient Education on Treatment Adherence and Satisfaction Among Acne Patients Receiving Once-daily Epiduo Gel Treatment in Primary Care Clinics Completed NCT02307266 Phase 4
40 Benzaknen® 5% Gel in Combination With Dermotivin® Soft Liquid Soap and Non-comedogenic Cetaphil® Dermacontrol Moisturizer SPF30 in the Treatment of Mild-to-moderate Acne Vulgaris Completed NCT02589405 Phase 4 Benzoyl Peroxide
41 A Study Comparing Aczone® Plus Differin® Versus Duac® Plus Differin® in Patients With Severe Facial Acne Completed NCT01231334 Phase 4 Dapsone plus Adapalene;Clindamycin/benzoyl peroxide plus Adapalene
42 Split-face Tolerability Comparison Between Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Versus Retin-A Micro® (Tretinoin Gel) Microsphere, 0.1% in Subjects With Acne Vulgaris Completed NCT01522456 Phase 4 Epiduo Gel;Retin-A Micro Microsphere 0.1%
43 The Use of Onexton in Moderate Acne Vulgaris for Patients With Skin of Color Completed NCT03402893 Phase 4 ONEXTON Topical Gel
44 Use of Aczone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Aczone 5% Gel Treatment Completed NCT01885910 Phase 4 Doxycycline 100mg;Aczone 5% gel
45 A Comparison of Differin® Gel, 0.1% vs. Tazorac® Cream, 0.1% vs. Differin® Gel, 0.1% 6-Week Treatment Switched to Tazorac® Cream, 0.1% 6-Week Treatment in Patients With Acne Vulgaris Completed NCT00469755 Phase 4 Adapalene Gel, 0.1%;Tazarotene Cream, 0.1%;Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%
46 Clinical Evaluation of Efficacy at 2 Weeks of Duac® Fixed Dose Combination Gel in Treatment of Facial Acne Vulgaris in Japanese Subjects Completed NCT02557399 Phase 4 Duac® fixed dose combination gel;ADA 0.1% gel;CLDM 1% gel
47 Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Pump, Cetaphil® DermaControl™ Moisturizer SPF 30, and Cetaphil® DermaControl™ Foam Wash Regimen in Student Athletes With Mild to Moderate Acne Vulgaris Completed NCT02249104 Phase 4 Adapalene/benzoyl peroxide gel, 0.1%/2.5%
48 A Single-blind, Randomized, Comparative Pilot Study Evaluating the Tolerability of Two Topical Combination Therapies in the Treatment of Acne Vulgaris Completed NCT00887484 Phase 4 BENZOYL PEROXIDE/ CLINDAMYCIN;BENZOYL PEROXIDE/ ADAPALENE
49 De Novo Lipogenesis of Sebaceous Glands in Acne Completed NCT02620813 Phase 4 Tretinoin;Isotretinoin
50 Effect of Adapalene 0.3% - Benzoyl Peroxide 2.5% Gel Versus Vehicle Gel on the Risk of Formation of Atrophic Acne Scars in Moderate to Severe Acne Subjects Completed NCT02735421 Phase 4 Adapalene 0.3% / BPO 2.5% gel;Vehicle gel

Search NIH Clinical Center for Neurofibromatosis, Type Ii

Inferred drug relations via UMLS 71 / NDF-RT 50 :


adapalene
azelaic acid
Benzoyl Peroxide
CLINDAMYCIN PHOSPHATE PWDR
Colloid sulfur
Desogestrel
ERYTHROMYCIN PWDR
Hexachlorophene
Isotretinoin
MECLOCYLINE SULFOSALICYLATE
Norethindrone
norethindrone acetate
resorcinol
RESORCINOL PWDR
Salicylic Acid
SALICYLIC ACID PWDR
Sulfur
SULFUR PWDR
SULFUR,COLLOIDAL
tazarotene
Tretinoin
TRETINOIN PWDR

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Neurofibromatosis, Type Ii cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Neurofibromatosis, Type Ii:
Laviv azficel-T, dermal fibroblasts for scarring
Embryonic/Adult Cultured Cells Related to Neurofibromatosis, Type Ii:
Skin-derived fibroblasts PMIDs: 21287562 10805306 23211390

Cochrane evidence based reviews: neurofibromatosis 2

Genetic Tests for Neurofibromatosis, Type Ii

Genetic tests related to Neurofibromatosis, Type Ii:

# Genetic test Affiliating Genes
1 Neurofibromatosis, Type 2 29 NF2
2 Acne 29

Anatomical Context for Neurofibromatosis, Type Ii

MalaCards organs/tissues related to Neurofibromatosis, Type Ii:

40
Skin, Ovary, Brain, Testes, Eye, Lung, Bone

Publications for Neurofibromatosis, Type Ii

Articles related to Neurofibromatosis, Type Ii:

(show top 50) (show all 15620)
# Title Authors PMID Year
1
Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. 56 6
8379998 1993
2
Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification. 24 56
17307835 2007
3
The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2. 56 24
15994874 2005
4
Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: a population-based study. 56 24
15190457 2004
5
Predictors of the risk of mortality in neurofibromatosis 2. 24 56
12235555 2002
6
Molecular genetic analysis of the NF2 gene in young patients with unilateral vestibular schwannomas. 24 56
12011146 2002
7
Paediatric presentation of type 2 neurofibromatosis. 56 24
10569966 1999
8
Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. 56 24
9643284 1998
9
Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. 56 24
8751853 1996
10
Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. 24 56
7747758 1994
11
A clinical study of type 2 neurofibromatosis. 24 56
1484939 1992
12
Neurofibromatosis type 2. 56 54
19476995 2009
13
Mutations and allelic loss of the NF2 gene in neurofibromatosis 2-associated skin tumors. 56 54
10771486 2000
14
Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. 56 54
8755919 1996
15
A missense mutation in the NF2 gene results in moderate and mild clinical phenotypes of neurofibromatosis type 2. 54 6
8566958 1996
16
Evaluating FMX-101 as a promising therapeutic for the treatment of acne. 42 61
32037906 2020
17
Acne Vulgaris: Treatment Made Easy for the Primary Care Physician. 61 42
32155276 2020
18
The Fate of Active Acne and Acne Scars Following Treatment With Fractional Radiofrequency 42 61
31860216 2019
19
Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. 6
27854360 2017
20
ACMG policy statement: updated recommendations regarding analysis and reporting of secondary findings in clinical genome-scale sequencing. 6
25356965 2015
21
ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. 6
23788249 2013
22
Empirical development of improved diagnostic criteria for neurofibromatosis 2. 56
21451418 2011
23
An update on age related mosaic and offspring risk in neurofibromatosis 2 (NF2). 56
19880713 2009
24
Ocular pathologic findings of neurofibromatosis type 2. 56
17353411 2007
25
Constitutional rearrangements of chromosome 22 as a cause of neurofibromatosis 2. 56
15235024 2004
26
Genotype-phenotype correlations for cataracts in neurofibromatosis 2. 56
14569124 2003
27
Neurofibromatosis 2 in a patient with a de novo balanced reciprocal translocation 46,X,t(X;22)(p11.2;q11.2). 56
12960214 2003
28
Evaluation of clinical diagnostic criteria for neurofibromatosis 2. 56
12473765 2002
29
Paxillin binds schwannomin and regulates its density-dependent localization and effect on cell morphology. 6
12118253 2002
30
Neurofibromatosis 2 and malignant mesothelioma. 56
12136076 2002
31
Maternal gene effect in neurofibromatosis 2: fact or artefact? 56
11732488 2001
32
Mononeuropathy multiplex as the initial manifestation of neurofibromatosis type 2. 56
11425952 2001
33
Monocular elevator paresis in neurofibromatosis type 2. 56
11342693 2001
34
Differential diagnosis of type 2 neurofibromatosis: molecular discrimination of NF2 and sporadic vestibular schwannomas. 56
9863591 1998
35
Long-term outcomes after radiosurgery for acoustic neuromas. 56
9811917 1998
36
Treatment of acoustic neuromas. 56
9811925 1998
37
Neurofibromatosis 2 6
20301380 1998
38
Somatic mosaicism: a common cause of classic disease in tumor-prone syndromes? Lessons from type 2 neurofibromatosis. 24 54
9718334 1998
39
The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. 56
9207339 1997
40
Mutational analysis and expression studies of the neurofibromatosis type 2 (NF2) gene in a patient with a ring chromosome 22 and NF2. 56
9225971 1997
41
A missense mutation in the neurofibromatosis 2 gene occurs in patients with mild and severe phenotypes. 6
8757035 1996
42
Ocular abnormalities in neurofibromatosis 2. 56
7485365 1995
43
Asbestos and mesothelioma: genetic lessons from a tragedy. 56
7479890 1995
44
Diagnostic issues in a family with late onset type 2 neurofibromatosis. 6
7666400 1995
45
Mutational analysis of patients with neurofibromatosis 2. 6
7913580 1994
46
Germline mutations in the neurofibromatosis type 2 tumour suppressor gene. 6
8081368 1994
47
National Institutes of Health Consensus Development Conference Statement on Acoustic Neuroma, December 11-13, 1991. The Consensus Development Panel. 56
8304846 1994
48
Presymptomatic diagnosis for neurofibromatosis 2 with chromosome 22 markers. 56
8414026 1993
49
A disease-associated germline deletion maps the type 2 neurofibromatosis (NF2) gene between the Ewing sarcoma region and the leukaemia inhibitory factor locus. 56
8102569 1993
50
Lens opacities in neurofibromatosis 2: further significant correlations. 56
8318482 1993